Neurotensin and Neurotensin Receptors in Stress-related Disorders: Pathophysiology & Novel Drug Targets.

Neurotensin PTSD anxiety depression ethanol addiction fear memory stress substance abuse.

Journal

Current neuropharmacology
ISSN: 1875-6190
Titre abrégé: Curr Neuropharmacol
Pays: United Arab Emirates
ID NLM: 101157239

Informations de publication

Date de publication:
03 Aug 2023
Historique:
received: 31 10 2022
revised: 20 01 2023
accepted: 10 02 2023
medline: 3 8 2023
pubmed: 3 8 2023
entrez: 3 8 2023
Statut: aheadofprint

Résumé

Neurotensin (NT) is a 13-amino acid neuropeptide widely distributed in the CNS that has been involved in the pathophysiology of many neural and psychiatric disorders. There are three known neurotensin receptors (NTSRs), which mediate multiple actions, and form the neurotensinergic system in conjunction with NT. NTSR1 is the main mediator of NT, displaying effects in both the CNS and the periphery, while NTSR2 is mainly expressed in the brain and NTSR3 has a broader expression pattern. In this review, we bring together up-to-date studies showing an involvement of the neuroten- sinergic system in different aspects of the stress response and the main stress-related disorders, such as depression and anxiety, post-traumatic stress disorder (PTSD) and its associated symptoms, such as fear memory and maternal separation, ethanol addiction, and substance abuse. Emphasis is put on gene, mRNA, and protein alterations of NT and NTSRs, as well as behavioral and pharmacological studies, leading to evidence-based suggestions on the implicated regulating mechanisms as well as their therapeutic exploitation. Stress responses and anxiety involve mainly NTSR1, but also NTSR2 and NTSR3. NTSR1 and NTSR3 are primarily implicated in depression, while NTSR2 and secondari- ly NTSR1 in PTSD. NTSR1 is interrelated with substance and drug abuse and NTSR2 with fear memory, while all NTSRs seem to be implicated in ethanol consumption. Some of the actions of NT and NTSRs in these pathological settings may be driven through interactions between NT and cortico- trophin releasing factor (CRF) in their regulatory contribution, as well as by NT's pro-inflammatory mediating actions.

Identifiants

pubmed: 37534788
pii: CN-EPUB-133345
doi: 10.2174/1570159X21666230803101629
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Grigorios Kyriatzis (G)

Laboratory of Pharmacology, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Institute of Neurophysiopathology, INP, CNRS, Aix-Marseille University, 13005 Marseille, France.

Michel Khrestchatisky (M)

Institute of Neurophysiopathology, INP, CNRS, Aix-Marseille University, 13005 Marseille, France.

Lotfi Ferhat (L)

Institute of Neurophysiopathology, INP, CNRS, Aix-Marseille University, 13005 Marseille, France.

Ekaterini Alexiou Chatzaki (EA)

Laboratory of Pharmacology, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Institute of Agri-Food and Life Sciences, University Research Centre, Hellenic Mediterranean University, 71410 Heraklion, Greece.

Classifications MeSH